vs
Side-by-side financial comparison of OFG BANCORP (OFG) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
OFG BANCORP is the larger business by last-quarter revenue ($184.3M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 0.9%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 2.8%).
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
OFG vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $184.3M | $129.7M |
| Net Profit | $55.9M | — |
| Gross Margin | — | 98.0% |
| Operating Margin | 25.7% | -25.0% |
| Net Margin | 30.3% | — |
| Revenue YoY | 0.9% | 73.4% |
| Net Profit YoY | 11.0% | — |
| EPS (diluted) | $1.27 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $184.3M | $129.7M | ||
| Q3 25 | $186.2M | $164.9M | ||
| Q2 25 | $182.4M | $114.4M | ||
| Q1 25 | $178.6M | $81.7M | ||
| Q4 24 | $182.7M | $74.8M | ||
| Q3 24 | $174.7M | $62.9M | ||
| Q2 24 | $179.8M | $54.1M | ||
| Q1 24 | $174.4M | $41.4M |
| Q4 25 | $55.9M | — | ||
| Q3 25 | $51.8M | $25.7M | ||
| Q2 25 | $51.8M | $-12.8M | ||
| Q1 25 | $45.6M | $-41.2M | ||
| Q4 24 | $50.3M | — | ||
| Q3 24 | $47.0M | $-54.8M | ||
| Q2 24 | $51.1M | $-70.4M | ||
| Q1 24 | $49.7M | $-136.1M |
| Q4 25 | — | 98.0% | ||
| Q3 25 | — | 99.0% | ||
| Q2 25 | — | 98.7% | ||
| Q1 25 | — | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | — | 97.4% | ||
| Q2 24 | — | 96.2% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | 25.7% | -25.0% | ||
| Q3 25 | 33.0% | 15.1% | ||
| Q2 25 | 36.1% | -11.1% | ||
| Q1 25 | 33.3% | -52.2% | ||
| Q4 24 | 28.9% | -81.2% | ||
| Q3 24 | 35.4% | -89.3% | ||
| Q2 24 | 39.6% | -125.1% | ||
| Q1 24 | 38.9% | -336.5% |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 27.8% | 15.6% | ||
| Q2 25 | 28.4% | -11.1% | ||
| Q1 25 | 25.5% | -50.4% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 26.9% | -87.1% | ||
| Q2 24 | 28.4% | -130.1% | ||
| Q1 24 | 28.5% | -328.9% |
| Q4 25 | $1.27 | $0.04 | ||
| Q3 25 | $1.16 | $0.28 | ||
| Q2 25 | $1.15 | $-0.14 | ||
| Q1 25 | $1.00 | $-0.47 | ||
| Q4 24 | $1.10 | $-0.71 | ||
| Q3 24 | $1.00 | $-0.70 | ||
| Q2 24 | $1.08 | $-0.91 | ||
| Q1 24 | $1.05 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0B | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $114.8M |
| Total Assets | $12.5B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $93.0M | ||
| Q3 25 | $740.3M | $110.9M | ||
| Q2 25 | $851.8M | $75.2M | ||
| Q1 25 | $710.6M | $61.9M | ||
| Q4 24 | $591.1M | $58.5M | ||
| Q3 24 | $680.6M | $36.4M | ||
| Q2 24 | $740.4M | $32.3M | ||
| Q1 24 | $754.4M | $43.3M |
| Q4 25 | $1.4B | $114.8M | ||
| Q3 25 | $1.4B | $73.6M | ||
| Q2 25 | $1.3B | $32.7M | ||
| Q1 25 | $1.3B | $32.8M | ||
| Q4 24 | $1.3B | $59.1M | ||
| Q3 24 | $1.3B | $-30.5M | ||
| Q2 24 | $1.2B | $15.1M | ||
| Q1 24 | $1.2B | $74.1M |
| Q4 25 | $12.5B | $605.2M | ||
| Q3 25 | $12.2B | $538.6M | ||
| Q2 25 | $12.2B | $555.3M | ||
| Q1 25 | $11.7B | $548.8M | ||
| Q4 24 | $11.5B | $594.1M | ||
| Q3 24 | $11.5B | $504.4M | ||
| Q2 24 | $11.3B | $551.1M | ||
| Q1 24 | $11.2B | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $217.7M | $60.7M |
| Free Cash FlowOCF − Capex | $199.3M | — |
| FCF MarginFCF / Revenue | 108.1% | — |
| Capex IntensityCapex / Revenue | 10.0% | — |
| Cash ConversionOCF / Net Profit | 3.90× | — |
| TTM Free Cash FlowTrailing 4 quarters | $345.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.7M | $60.7M | ||
| Q3 25 | $39.5M | $14.3M | ||
| Q2 25 | $35.9M | $5.0M | ||
| Q1 25 | $83.1M | $-42.2M | ||
| Q4 24 | $252.5M | $-35.7M | ||
| Q3 24 | $58.1M | $-42.5M | ||
| Q2 24 | $95.1M | $-40.2M | ||
| Q1 24 | $61.0M | $-119.0M |
| Q4 25 | $199.3M | — | ||
| Q3 25 | $35.5M | $14.2M | ||
| Q2 25 | $31.8M | — | ||
| Q1 25 | $78.7M | — | ||
| Q4 24 | $231.2M | — | ||
| Q3 24 | $51.8M | — | ||
| Q2 24 | $90.4M | $-40.3M | ||
| Q1 24 | $54.8M | — |
| Q4 25 | 108.1% | — | ||
| Q3 25 | 19.1% | 8.6% | ||
| Q2 25 | 17.4% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 126.5% | — | ||
| Q3 24 | 29.6% | — | ||
| Q2 24 | 50.3% | -74.5% | ||
| Q1 24 | 31.4% | — |
| Q4 25 | 10.0% | — | ||
| Q3 25 | 2.1% | 0.1% | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 11.7% | — | ||
| Q3 24 | 3.6% | 0.0% | ||
| Q2 24 | 2.6% | 0.2% | ||
| Q1 24 | 3.5% | 0.0% |
| Q4 25 | 3.90× | — | ||
| Q3 25 | 0.76× | 0.56× | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 1.82× | — | ||
| Q4 24 | 5.02× | — | ||
| Q3 24 | 1.24× | — | ||
| Q2 24 | 1.86× | — | ||
| Q1 24 | 1.23× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OFG
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
